ArticleHeliyon2023
Synthesis and characterization of bovine serum albumin-coated copper sulfide nanoparticles as curcumin nanocarriers.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Surface charge-dependent effects of BSA-curcumin nanoparticles combined with amikacin in antimicrobial photodynamic therapy: A pilot In Vivo study of multidrug-resistant Pseudomonas aeruginosa skin infection.Lasers in medical science · 2026Article
- Green synthesis of copper oxide nanoparticles with Calendula officinalis plant extract and investigation of its toxicity.Scientific reports · 2026Article
- Innovative γ-Oryzanol and KC2 Based Lipid Nanoparticles: OryKL Platform Provides Safe and Efficient In Vivo mRNA Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Periodate-Mediated Cross-Linking for the Preparation of Catechol Conjugated Albumin Nanoparticles Used for in Vitro Drug Delivery.ACS applied bio materials · 2025Article
- Unleashing of cytotoxic effects of thymoquinone-bovine serum albumin nanoparticles on A549 lung cancer cells.Open life sciences · 2024Article
- The Advancement and Obstacles in Improving the Stability of Nanocarriers for Precision Drug Delivery in the Field of Nanomedicine.Current topics in medicinal chemistry · 2024Review
- Dopamine-Conjugated Bovine Serum Albumin Nanoparticles Containing pH-Responsive Catechol-V(III) Coordination for In Vitro and In Vivo Drug Delivery.Biomacromolecules · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is among the most common causes of death in the world that affects a large number of people every year. Curcumin is one of the natural anticancer therapeutics with little or no negative effects. However, due to its hydrophobic nature, poor bioavailability, limited gastrointestinal uptake, and fast metabolism, its therapeutic applications are constrained. Therefore, the Bovine Serum Albumin-Coated Copper Sulfide anoparticles (CuS@BSA) for curcumin (CUR) drug delivery were synthesized and characterized, and then curcumin release from the nanosystem. Hemotoxicity, and cytotoxicity was investigated. This study involved the one-step synthesis of CuS@BSA nanoparticles first, followed by the addition of CUR. Then the synthesized nanoparticles were characterized employing Scanning Transient Electron Microscopy (STEM), Ultraviolet-visible spectroscopy (UV-vis) and Fourier-transform infrared spectroscopy (FT-IR) techniques. The Size and surface charge (zeta potential) of synthesized nanoparticles were determined by Dynamic Light Scattering (DLS) to be 120 nm and -13 eV, respectively. The results showed that the CUR loading was around 15% and also the release pattern of CUR was dependent on pH and increased in an acidic environment. The results of the hemolysis assay showed that the synthesized nanoparticles are not hemotoxic. The investigation of the cytotoxic effects of synthesized nanoparticles on cancer cells demonstrated that CuS@BSA nanoparticles did not exhibit any toxicity and therefore are an appropriate candidate for drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.